Advanced glycation end products are associated with arterial stiffness in type 1 diabetes

J Endocrinol. 2014 Jun;221(3):405-13. doi: 10.1530/JOE-13-0407. Epub 2014 Mar 28.

Abstract

The aim of this study was to investigate the relationship between advanced glycation end products (AGEs) and arterial stiffness (AS) in subjects with type 1 diabetes without clinical cardiovascular events. A set of 68 patients with type 1 diabetes and 68 age- and sex-matched healthy subjects were evaluated. AGEs were assessed using serum concentrations of N-carboxy-methyl-lysine (CML) and using skin autofluorescence. AS was assessed by aortic pulse wave velocity (aPWV), using applanation tonometry. Patients with type 1 diabetes had higher serum concentrations of CML (1.18 vs 0.96 μg/ml; P=0.008) and higher levels of skin autofluorescence (2.10 vs 1.70; P<0.001) compared with controls. These differences remained significant after adjustment for classical cardiovascular risk factors. Skin autofluorescence was positively associated with aPWV in type 1 diabetes (r=0.370; P=0.003). No association was found between CML and aPWV. Skin autofluorescence was independently and significantly associated with aPWV in subjects with type 1 diabetes (β=0.380; P<0.001) after adjustment for classical cardiovascular risk factors. Additional adjustments for HbA1c, disease duration, and low-grade inflammation did not change these results. In conclusion, skin accumulation of autofluorescent AGEs is associated with AS in subjects with type 1 diabetes and no previous cardiovascular events. These findings indicate that determination of tissue AGE accumulation may be a useful marker for AS in type 1 diabetes.

Keywords: advanced glycation end products; arterial stiffness; arteriosclerosis; pulse wave velocity; skin autofluorescence; type 1 diabetes mellitus.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aorta / physiopathology
  • Biomarkers / blood
  • Biomarkers / metabolism
  • Blood Glucose / metabolism
  • Case-Control Studies
  • Diabetes Mellitus, Type 1 / blood*
  • Diabetes Mellitus, Type 1 / physiopathology*
  • Female
  • Glycated Hemoglobin / metabolism
  • Glycation End Products, Advanced / blood*
  • Glycation End Products, Advanced / metabolism
  • Humans
  • Linear Models
  • Lysine / analogs & derivatives
  • Lysine / blood
  • Male
  • Middle Aged
  • Optical Imaging / methods
  • Pulse Wave Analysis
  • Skin / metabolism
  • Spectrometry, Fluorescence
  • Vascular Stiffness*

Substances

  • Biomarkers
  • Blood Glucose
  • Glycated Hemoglobin A
  • Glycation End Products, Advanced
  • N(6)-carboxymethyllysine
  • Lysine